TORONTO, May 18, 2017 /PRNewswire/ --
MolecuLight is pleased to announce the
execution of an exclusive global distribution agreement with Smith
& Nephew to distribute the MolecuLight
i:X™ Imaging Device
product line.
The distribution agreement represents
an important milestone to expand market access with a
highly-respected market leader with an established presence across
a broad customer base and a deep knowledge of the clinician
need.
"This is a historic day for MolecuLight," says Craig Kennedy, CEO. "This partnership
further proves our continued commitment to empower clinicians with
knowledge allowing them to strengthen their clinical decision
making."
Andy Weymann, MD, Chief Medical
Officer at Smith & Nephew says: "The
MolecuLight i:X enables healthcare
professionals to see what they have never been able to see before,
the actual accumulation of fluorescent bacteria in a wound, even
when not visible to the naked eye, among other benefits like
guiding debridement and wound cleansing, wound measurement, as well
as enhance the conversation between the clinician and the
patient. MolecuLight i:X enhances
clinicians' ability to choose the right therapy, at the right time
for their
patient[1],[2]."
"This agreement is a key step for our company and its
shareholders and helps us deliver on our pledge to advance wound
healing through innovation," says Dr Ralph
DaCosta, Founder, Chief Scientific Officer and Board
Director. "Our initial customer and patient experience has been
excellent. We are confident that Smith & Nephew's
longstanding dedication to clinicians and patient wellbeing will
help rapidly expand clinical adoption."
The device is currently CE Marked and approved by Health
Canada and is available in the European Union and in
Canada. The MolecuLight i:X is
pending De Novo approval in the USA.
About MolecuLight
MolecuLight Inc. is a privately owned, Canadian medical imaging
company delivering real-time fluorescence image-guidance solutions
that provide clinicians with new information about wound bacterial
burden and wound size to assist clinicians in making improved
diagnostic and treatment decisions. To learn more visit
http://www.moleculight.com .
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic
Reconstruction, Advanced Wound Management, Sports
Medicine and Trauma & Extremities, Smith & Nephew
has around 15,000 employees and a presence in more than 100
countries. Annual sales in 2015 were more than $4.6 billion. Smith & Nephew is a member of
the FTSE100 (LSE:SN, NYSE:SNN).
1. Wu YC, Smith M, Chu A, Lindvere-Teene L, Starr
D, Tapang K, Wong O, Linden R, DaCosta RS. Handheld fluorescence
imaging device detects subclinical wound infection in an
asymptomatic patient with chronic diabetic foot ulcer: a case
report. Int Wound J. 2016 Aug;13(4):449-53.
2. DaCosta RS, Kulbatski I, Lindvere-Teene L, Starr
D, Blackmore K, Silver JI, Opoku J, Wu YC, Medeiros PJ, Xu
W, et al. Point-of-care autofluorescence imaging for
real-time sampling and treatment guidance of bioburden in chronic
wounds: first-in-human results. PLoS One. 2015 Mar 19;10(3).
Catherine Theodoropoulos,
416.673.6515, catherinet@moleculight.com